Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Other product development or post-marketing obligations required by the FDA

3 evidence topics · 4 sources

Post-marketing requirements or commitments

Not applicable.